{"id":"NCT00549302","sponsor":"Eli Lilly and Company","briefTitle":"Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs","officialTitle":"An Extension Study to Evaluate the Long-Term Safety and Efficacy of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients With Pulmonary Arterial Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-12","primaryCompletion":"2012-02","completion":"2012-02","firstPosted":"2007-10-25","resultsPosted":"2013-02-18","lastUpdate":"2013-04-09"},"enrollment":357,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension, Pulmonary"],"interventions":[{"type":"DRUG","name":"tadalafil","otherNames":["LY450190","Cialis","IC351"]},{"type":"DRUG","name":"tadalafil","otherNames":["LY450190","Cialis","IC351"]}],"arms":[{"label":"20 mg tadalafil","type":"ACTIVE_COMPARATOR"},{"label":"40 mg tadalafil","type":"ACTIVE_COMPARATOR"}],"summary":"Study to determine the long term safety of tadalafil in patients with increased blood pressure in the blood vessel that carries blood from the right heart to the lungs and to see if it will keep the disease from getting worse.","primaryOutcome":{"measure":"Number of Participants With Adverse Events (AEs)","timeFrame":"Baseline (Double-Blind Period) up to Week 243 (End of Open-Label Period)","effectByArm":[{"arm":"Tadalafil 20 mg or 40 mg Double-Blind and 40 mg Open-Label","deltaMin":184,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":10,"countries":["United States","Belgium","Canada","France","Germany","Ireland","Italy","Japan","Spain","United Kingdom"]},"refs":{"pmids":["22818063"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":184,"n":357},"commonTop":["Headache","Diarrhoea","Nasopharyngitis","Back pain","Oedema peripheral"]}}